| Literature DB >> 34702648 |
Kristen McAlpine1, Luke T Lavallée2, Rodney H Breau3.
Abstract
Surrogate endpoints have the potential to expedite results from clinical trials. However, a surrogate endpoint may not always be a patient-important outcome. Surrogate endpoints must be validated to ensure that they do not expose patients to unnecessary treatment-related toxicity.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34702648 DOI： 10.1016/j.euf.2021.10.008
Source DB: PubMed Journal: Eur Urol Focus ISSN： 2405-4569